Studies relate FGF21 resistance in patients with obesity to the release of pro-inflammatory molecules and microRNAs, leading to an increase in FGF21 plasma levels and decreased expression of the FGF21 receptor complex [45]. The gene discussed is FGF21; the disease is obesity disorder.